1. Riehm H, Feickert HJ, Schrappe M, Henze G, Schellong G . Therapy results in five ALL-BFM studies since 1970. Complications of risk factors for prognosis Haematol Blood Transfus 1987 30: 139–146
2. Kamps WA, Bökkerink JPM, Hählen K, Van den Berg-de Ruiter E, Smets LA, De Vaan GAM, Weening RS, Van Weerden JF, Van Wering ER, Van der Does-van den Berg A . Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM 86 without cranial radiotherapy: results of DCLSG Protocol ALL-7 (1988–1991) Blood 1999 94: 1226–1236
3. Schrappe M, Reiter A, Ludwig W-D, Harbott J, Zimmermann M, Hiddemann W, Niemeyer Ch, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H . Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90 Blood 2000 95: 3310–3322
4. Masera G, Gadner H, Kamps WA, Otten J, Philippe N, Schuler D, Riehm H . The treatment of childhood acute lymphoblastic leukemia Int J Pediatr Hematol/Oncol 1998 5: 141–144
5. Rizzari C, Valsecchi MG, Aricò M, Conter V, Testi A, Barisone E, Casale F, Lo Nigro L, Rondelli R, Basso G, Santoro N, Masera G . Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin–Frankfurt–Münster-based treatment: results of the randomized 9102 Intermediate-Risk Childhood Acute Lymphoblastic Leukemia Study – a report from the Associazione Italiana Ematologia Oncologia Pediatrica J Clin Oncol 2001 19: 1297–1303